Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Research & Development is the aggregate amount of research and development expenses during the year. Saakshi Medtech and Panels's Research & Development for the
six
months ended in Mar. 2026 was ₹0.0 Mil.
Its Research & Development for the trailing twelve months (TTM) ended in Mar. 2026 was ₹0.0 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Saakshi Medtech and Panels Research & Development Chart
Saakshi Medtech and Panels Research & Development Calculation
This is the expense the company spent on research and development.
Research & Development for the trailing twelve months (TTM) ended in Mar. 2026 adds up the semi-annually data reported by the company within the most recent 12 months, which was ₹0.0 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Research & Development of ₹0.0 Mil mean?
Saakshi Medtech and Panels (NSE:SAAKSHI) has a Research & Development of ₹0.0 Mil as of Mar. 2026. Research and development expense is the total cost for research and development activities. View historical data on Saakshi Medtech and Panels and its competitors.
Is Saakshi Medtech and Panels' Research & Development too high?
Saakshi Medtech and Panels' current Research & Development is ₹0.0 Mil. Overall, Saakshi Medtech and Panels has a GF Score™ of 50/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Saakshi Medtech and Panels' Research & Development compare to VRT and BE?
Saakshi Medtech and Panels' Research & Development of ₹0.0 Mil can be compared against companies in the Industrial Products industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Research & Development for an Industrial Products company?
A good Research & Development depends on the Industrial Products industry context. However, Research & Development should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Research & Development mean?
A high Research & Development can signal that a stock is expensive relative to its fundamentals. Research and development expense is the total cost for research and development activities. View historical data on Saakshi Medtech and Panels and its competitors. Saakshi Medtech and Panels's current Research & Development is ₹0.0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Saakshi Medtech and Panels stock overvalued right now?
Based on GuruFocus' analysis, Saakshi Medtech and Panels (NSE:SAAKSHI) is currently considered Significantly Overvalued. The stock's GF Value™ is ₹220.57, compared to a current price of ₹345.40 — trading 56.6% above its estimated fair value. The current Research & Development is ₹0.0 Mil. Saakshi Medtech and Panels' overall GF Score™ is 50/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Research & Development calculated?
Research & Development is calculated from a company's financial statements. For Saakshi Medtech and Panels (NSE:SAAKSHI), the current Research & Development is ₹0.0 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Saakshi Medtech and Panels (NSE:SAAKSHI) Overvalued in 2026?
Based on GuruFocus' analysis, Saakshi Medtech and Panels stock appears to be overvalued.
The current stock price of ₹345.40 is trading 56.6% above its estimated GF Value™ of ₹220.57.
GuruFocus considers Saakshi Medtech and Panels to be Significantly Overvalued.
Key valuation signals for NSE:SAAKSHI:
Research & Development: ₹0.0 Mil
GF Value™: ₹220.57 vs. price of ₹345.40 (56.6% above fair value)
No single metric tells the full story. See the NSE:SAAKSHI stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Saakshi Medtech and Panels Ltd is a diversified company engaged in manufacturing Electrical Control Panels and Cabinets used in elevators, air compressors, renewable energy industry, oil & gas exploration industry, electrical vehicle charging stations, medical X-Ray Systems used in healthcare industry, fabrication works for locomotives, and wire harness division for their captive consumption in electrical control panels and for supply to air compressor industry. Their comprehensive solutions include design, process engineering, and manufacturing including fabrication, assembly, and testing facilities. It designs, programs, and assembles Electrical Control Panels and Cabinets comprising microcontrollers, programmable logic controllers, and SCADA systems.
50GF Score
Get the complete analysis for NSE:SAAKSHI
Research & Development is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:SAAKSHI has been successfully added to your 
